Kornimate/medical-research-clean huggingface dataset:
shockwave therapy for plantar fasciitis rct

Conditions: Plantar Fascitis

Summary: inflammation of the plantar fascia is known as plantar fasciitis and is commonly seen in active or overweight individuals. it can be treated via conservative or surgical therapies. extracorporeal shockwave therapy has shown promise in the treatment of plantar fasciitis. several studies have compared the effects of different types of extracorporeal shockwave therapy (radial and focused) with other forms of conservative treatment in patients with chronic plantar fasciitis. no study has yet compared the effect of radial vs. focused shockwave therapy on pain in this population.

plantar fasciitis is a common foot problem that affects 3.8 per 1,000 persons in the united states. it is characterized by inflammation of the plantar fascia, a fibrous tissue which connects the calcaneus to the metatarsal heads, and is often seen in individuals who are overweight and/or participate frequently in weight-bearing endurance activities such as running. pain is typically at its highest during the first steps in the morning, although it can also occur with prolonged weightbearing. plantar fasciitis can be treated via conservative or surgical measures, although surgery is considered as the last resort. in recent years, extracorporeal shockwave therapy has emerged as an alternative conservative method for treating plantar fasciitis. there are two types -- radial and focused shockwave therapy. focused therapy creates deeper-penetrating, higher-energy shockwaves, whereas radial therapy produces more superficial shockwaves that can treat a wider area of pathology. randomized controlled trials have compared focused and radial shockwave therapy to placebo and other conservative measures in the treatment of chronic plantar fasciitis and overall demonstrated benefit. only one study has directly compared radial and focused shockwave therapy in this population, although pain was not an outcome of focus in the study. the current study aims to collect patient-reported outcomes on both pain and function following radial vs. focused shockwave therapy vs. control therapy.

Eligibility criteria:
inclusion criteria: * patients presenting with a clinical diagnosis of chronic plantar fasciitis (\>3 months) that has been recalcitrant to other treatments * minimum vas pain of 40/100 (4/10; morning pain when taking first steps, pain after prolonged walking/standing) * english-speaking exclusion criteria: * cortisone injection within the past 3 months * platelet-rich plasma injection within the past 6 months * history of previous foot surgery * bilateral heel pain * coagulopathies or use of anti-coagulants * local and systemic neurologic or vascular insufficiencies * rheumatologic disorders * systemic inflammatory disorders * active or chronic infection in the area * lower extremity bone disorders (e.g., paget's disease, osteomyelitis) * calcaneal fractures * nerve entrapment * ruptures in tendon * non-english speaking
atp level and cough sensitivity to atp in subjects with refractory/unexplained chronic cough

Conditions: Refractory/Unexplained Chronic Cough

Summary: this is a cross-sectional study to investigate atp level in induced sputum and cough sensitivity to atp in subjects with refractory/unexplained chronic cough. 60 patients with refractory/unexplained chronic cough and 30 matched healthy controls were recruited. demographic data, clinical characteristic, cough sacles and medical history records were collected. cough chanllage(atp and capsaicin) and atp measurement in sputum were conducted.the difference of sputum atp level between patients and control and the correlation between sputum atp level and cough sensitivity to atp were analyzed.


Eligibility criteria:
inclusion criteria for patients: 1. ≥18 years old 2. cough as sole symptom lasting ≥6 months 3. cough visual analogue score ≥30mm 4. diagnosed as rcc/ucc according to guidelines exclusion criteria for patients: 1. smoking currently or in the past 6 months, or a smoking history of \>20 pack-year 2. a forced expiratory volume in 1 second/forced vital capacity ratio \<70%; 3. use of inhaled/oral corticosteroid, bronchodilators, anti-allergic medicine, antitussive medicine or anti-reflux treatment in the past 1 week; 4. a history of acute respiratory infection in the past 4 weeks; 5. a history of severe disease (cancer, acute coronary syndrome and so on). healthy control aged ≥18 years old are included. exclusion criteria are as follow: 1. smoking currently or in the past 6 months, or a smoking history of \>20 pack-year 2. a forced expiratory volume in 1 second/forced vital capacity ratio \<70% 3. a history of acute respiratory infection in the past 4 weeks 4. posstive findings of chest radiography 5. a history of chronic respiratory disease and allergic disease 6. any signs of cough hypersensitivity

Keywords: refractory/unexplained chronic cough cough sensitivity adenosine triphosphate
a study to evaluate the safety and antiviral effect of multiple doses of abt-493 and abt-530 in adults with genotype 1 hepatitis c virus (hcv)

Conditions: Chronic Hepatitis C; Hepatitis C Virus; Compensated Cirrhosis

Summary: the purpose of this study is to evaluate the safety and antiviral effect of multiple doses of abt-493 and abt-530 in adults with genotype 1 hcv.


Eligibility criteria:
inclusion criteria: * chronic hcv infection prior to study enrollment. * screening laboratory result indicating hcv genotype 1-infection. * subject has plasma hcv rna level greater than 10,000 iu/ml at screening. * per local standard, subject is considered to be non-cirrhotic or to have compensated cirrhosis. exclusion criteria: * history of severe, life-threatening or other significant sensitivity to any drug. * positive test result for hepatitis b surface antigen (hbsag) or anti-human immunodeficiency virus antibody (hiv ab). * prior therapy for the treatment of hcv. * any current or past clinical evidence of child pugh b or c classification of clinical history of liver decompensation including ascites (noted on physical exam), variceal bleeding or hepatic encephalopathy. * any cause of liver disease other than chronic hcv infection.

Keywords: chronic hepatitis c cirrhosis child pugh a hepatitis c virus compensated cirrhosis hepatitis c genotype 1 hepatitis c interferon-free cirrhotic
tranexamic acid for unilateral total knee arthroplasty

Conditions: Blood Loss

Summary: total knee arthroplasty is often associated with excessive postoperative bleeding due to increased fibrinolysis. hence, the objective of the proposed of this multicentre study is to determine the peri-operative bleeding comparing the application of topical and intravenous tranexamic acid with the habitual surgical haemostasis.

objectives: 1. principal: to assess if the topical and intravenous tranexamic acid reduce less or at least than 20% the blood losses with respect to the habitual haemostasia in patients, after unilateral total knee arthroplasty. 2. secondary: to assess the treatment safety. to perform a cost- analyses. methods: randomized, multicentre, open and parallel clinical trial with three comparative groups: topical tranexamic acid, intravenous tranexamic acid and habitual haemostasia. in all patients, a single drainage of 8mm will be inserted in the joint, and it will remain closed during one hour after the closure of the skin. nº of participant centres: 2. random allocation will be centralised in "hospital de la santa creu i sant pau". main outcome: total blood loss (ml) in the post-operative period collected by the habitual drain system ). secondary outcomes: total blood loss (ml)and hidden blood calculated by nadler's formula. proportion of patients with blood transfusion, complications of surgery wound, haemoglobin pre and post-operative, units of blood transfused, post-operative mortality, days of hospital stay, safety of interventions assessed.direct cost analysis. substudy: pharmacokinetic study. the first 24 patients included in "hospital de la santa creu i sant pau" for tranexamic acid (12 topical- 12 intravenous) to determine: 1. plasmatic concentrations of tranexamic acid 2. in topical and intravenous tranexamic acid administration determine the absorption rate and drug bioavailability by these routes: maximum plasma concentration, time to reach cmax, auc, and half-life.

Eligibility criteria:
inclusion criteria: * unilateral total knee arthroplasty * the patient consent to participate exclusion criteria: * antecedent of thromboembolic disease * patient with cardiac alterations of the rhythm * patients with valvular cardiac prosthesis * patients with pro-thrombotic alterations of coagulation * treatment with anticonceptive drugs

Keywords: primary knee arthroplasty tranexamic acid topical
intergard synergy post-marketing surveillance study

Conditions: Aortic Aneurysm, Abdominal; Occlusive Disease of Artery of Lower Extremity

Summary: the purpose of the study is to assess the performance and safety of the intergard synergy vascular graft.

study of the device in patients with aneurysmal and occlusive disease of the abdominal aorta and peripheral arteries.

Eligibility criteria:
inclusion criteria: * patients requiring an intergard synergy vascular graft exclusion criteria: * patients with contra-indications per intergard synergy vascular graft * patients with current graft infection * patients with a known allergy to collagen, triclosan or silver acetate * patients who require urgent or emergent surgery
the effect of yoga in chronic low back pain

Conditions: Low Back Pain

Summary: the purpose of this study is to determine if yoga is an effective intervention in treating individuals with chronic low back pain (lbp).

chronic lbp is a major public health problem associated with functional and psychological disability. conservative interventions are often prescribed to people suffering from chronic lbp, but alternative interventions like yoga are not well researched. the regulator practice of yoga may improve pain, disability or quality of life in people with chronic lbp. study participation will last approximately 24 weeks. yoga sessions will last 12 weeks for 2 one hour sessions per week

Eligibility criteria:
inclusion criteria: * a history of chronic lbp with degenerative joint or disc disease \> than 3 months (47-48) * present with at least minimal pain (3 out on a 0 - 10 pain scale where 0 = no pain, 10 = maximum pain imaginable) * disability (30% or more per oswestry disability scale), * score more than 24 on the folstein mini-mental state exam * english comprehending individuals naïve to structured yoga practice exclusion criteria: * known current pregnancy * claustrophobia * glaucoma * significant or chronic decline in immune function such as reported immune related diagnosis like pneumonia or systemic infection * lbp resulting from something other than disc or joint disease * spinal stenosis, spinal fusion or other orthopedic surgery in the past six months * mental disease/psychosis such as dementia * prior history of chronic neurological disorders (e.g. stroke, parkinson's disease, multiple sclerosis) * fibromyalgia * radiculopathy * standard mri exclusion criteria * inability to make regular time commitments * no transportation means to the scheduled yoga sessions * experience with regular practice of yoga within the past year.

Keywords: chronic low back pain low back pain yoga
triamcinolone versus topical treatment in post operative phacoemulsification

Conditions: Ocular Inflammation

Summary: cataract extraction is one of the most common operative procedures performed throughout the world. conventionally, patients are discharged with postoperative drops of steroids and antibiotics or a combination of both. these drops are to be administered for 2-6 weeks depending on individual eye unit protocol. many patients find the postoperative drops arduous and non-compliance can cause prolonged inflammation and discomfort. patients with cognitive, physical and visual impairments require assistance from family or community nurses to administer drops. a single perioperative injection of triamcinolone has been shown to be an effective replacement for drops postoperatively in two previous studies 1, 2. aims \& objectives the aim of this study is to see if a single orbital floor injection of triamcinolone is equivalent to conventional steroid and antibiotic drops used post operatively in uneventful phacoemulsification surgery in treating postoperative inflammation.

this is a prospective randomized control trial of 80 patients undergoing routine phacoemulsification cataract extraction. the patients were randomly assigned to receive the triamcinolone injection or post operative topical treatment of g maxitriol qds 1/52 tapering over one month. forty mg of triamcinolone was injected inferior temporally immediately post operatively prior to undraping the patient in theatre in those randomized to this group. the patients were reviewed at week one and at one month.

Eligibility criteria:
inclusion criteria: * uncomplicated cataract surgery, ability to attend follow appointments at one week and one month exclusion criteria: * included premorbid ocular pathology including previous ocular inflammation and glaucoma, previous ocular surgery, history of cmo, diabetes, concurrent use of systemic anti-inflammatories including inhaled or topical therapy, history of systemic inflammation, inability to attend follow up appointments at one week and one month, complicated cataract surgery

Keywords: orbital floor triamcinolone phacoemulsification post op inflammation cmo
effect of vegetable oils for use by the snack food industry on plasma lipid levels and inflammatory markers

Conditions: Hyperlipidemias; Metabolic Syndrome X; Cardiovascular Diseases

Summary: the current study is designed to assess the effect of a conventional cooking oil (hydrogenated oil) and a reformulated fat low in trans fatty acids on cardiovascular disease risk factors.

it is known that in subjects with high cholesterol levels that substitution of hydrogenated fat (high in trans fat) with vegetable oil results in higher levels of total and ldl cholesterol ("bad" cholesterol). there has been tremendous interest within the food industry to identify cooking fats that have the physical properties necessary to make shelf stable products and have textural characteristics similar to existing products but that also favorably affects risk factors for coronary heart disease (chd) such as ldl cholesterol levels and inflammatory markers. the current study is designed to assess the effect of a conventional cooking oil (hydrogenated oil) and a reformulated fat low in trans fatty acids on cardiovascular disease risk factors.

Eligibility criteria:
inclusion criteria: * gender: female * age: 50-85 years * ldl-c concentrations \>120 mg/dl * menopausal status: postmenopausal exclusion criteria: * use of medications known to affect lipid metabolism * untreated thyroid disease * diabetes mellitus * abnormal kidney function * abnormal liver function * smoking * alcohol consumption \> 2 drinks/day
comparison between prednisolone and dexamethasone on mortality in patients on oxygen therapy, with covid-19

Conditions: Coronavirus Infection

Summary: the aim of the study is to evaluate two differents regimens of corticosteroids (prednisolone versus dexamethasone) on d28 mortality in patients with covid 19 pneumonia requiring oxygen supplementation

low-dose glucocorticoid treatment is the only medication showing a significant reduction in mortality in cases of covid-19 pneumonia requiring oxygen supplementation or ventilatory support. intravenous or oral dexamethasone are well evaluated in randomized study but other oral corticosteroids are not. compared to dexamethasone, prednisolone is more available in france and easily taken by patients, especially in case of home medical care. the pharmacokinetics/pharmacodynamics of prednisolone and dexamethasone are different. to obtain similar effects, prednisolone should be theoretically taken twice a day and at a superior dose than the strict prednisone equivalence of 6mg dexamethasone.

Eligibility criteria:
inclusion criteria: * patient ≥ 18 years old * patient with sars-cov-2 pneumopathy documented by nasopharyngeal or bronchoalveolar lavage fluid rt-pcr or any documented clinical symptoms support by ct scan * patient with spao2 ≤ 94 % in room air (90% for patient with respiratory failure) and requiring an oxygen therapy * negative pregnancy test for women of childbearing age * informed and written informed consent (ic) obtained * patients with affiliation to the social security system exclusion criteria: * patient with corticosteroids as background treatment (≥ 10 mg equivalent) * patient under supplemental oxygen \> 6 l/min * immunocompromised patient (aids, bone marrow or solid organ transplants, etc.) * patient who received a corticosteroid dose within 3 days for covid-19 * medical history of hypersensitivity to prednisolone or dexamethasone; or lactose / galactose (excipients with known effect) * another active virus such hepatitis, herpes, varicella, shingles .... * psychotic state not controlled by treatment

Keywords: coronavirus infections sars-cov-2 corticostéroïdes severe form of covid-19
a study evaluating fmc-376 in participants with kras g12c mutated solid tumors

Conditions: Advanced Solid Tumors With KRAS G12C Mutations; Solid Tumor, Adult; Unresectable Solid Tumor; Metastatic Solid Tumor; Non Small Cell Lung Cancer; Colorectal Cancer; KRAS G12C; Pancreatic Cancer

Summary: the goal of this clinical trial is to evaluate fmc-376 in participants with advanced solid tumors with kras g12c mutations. this clinical trial will be conducted in 3 parts: phase 1a (dose escalation), phase 1b (dose expansion), and phase 2 (cohort expansion). multiple dose levels in participants with advanced solid tumors will be evaluated.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumors with kras g12c mutation * received and progressed or been intolerant to prior standard therapy or standard therapy is considered inappropriate or an investigational agent is considered standard of care * eastern cooperative oncology group (ecog) performance status 0 or 1 * adequate hematological, renal, and hepatic function * agrees not to participate in another interventional study while receiving study drug exclusion criteria: * leptomeningeal disease or carcinomatous meningitis * clinically significant toxicity resulting from prior cancer therapies * known or suspected hypersensitivity to fmc-376 or any components of the study drug * condition that would interfere with study drug absorption * any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data
safety and efficacy study to compare a 4% dimethicone foam and nix cream rinse (1% permethrin) in the control of head lice

Conditions: Head Lice

Summary: the purpose of this study was to evaluate the efficacy of a dimethicone foam in the control of head lice and to compare the efficacy to a permethrin based product.


Eligibility criteria:
inclusion criteria: * 4 - 85 years of age * active head lice infestation of at least ≥ 10 live lice * short hair (hair no longer than 2 inches below the neck) or long hair (hair 2 inches below the neck to mid back) exclusion criteria: * had received or used an investigational new drug within the 30 days immediately preceding the study * used any form of head lice treatment whether prescription, over-the-counter, or a home remedy for at least fourteen days prior to their study visit * used topical medication of any kind on the hair for a period of 48 hours prior to the visit * had a history of allergy to rag weed, permethrin, or mineral oil, or had taken trimethoprim or cotrimoxazole at evaluation or during the previous four weeks * female subjects that were pregnant or breast feeding
comparison of dcb and des for severe calcification of de novo lesion in elderly chd

Conditions: Coronary Artery Disease

Summary: the goal of this clinical trial was to compare the effectiveness of drug balloons versus drug-coated stents in calcified lesions in elderly coronary artery disease. the main question it aims to answer is whether the application of dcb is non-inferior to des for in situ large vessel calcified lesions in the elderly coronary arteries. and to develop a method to precisely identify the nature and extent of calcified lesions and to rationalize the choice of pretreatment.


Eligibility criteria:
inclusion criteria: * 1. older than 60 years of age. * 2. meeting the indications for coronary intervention. * 3. ivus examination suggests severe calcified lesions (calcification angle \> 270° at the target lesion) or oct examination suggests severe calcified lesions (calcification angle \> 180° and/or length \> 5 mm and/or thickness \> 0.5 mm); * 4. target lesion vessel diameter \> 2.5 mm exclusion criteria: * 1. inability to provide written informed consent. * 2. unable to administer antiplatelet agents and anticoagulant therapy; have allergies to heparin, contrast agents, etc. * 3. the subject is participating in another uncompleted clinical trial * 4. life expectancy \<1 year. * 5. non-in situ vascular lesions. * 6. cardiogenic shock. * 7. patients with hemodynamic instability
tolerance and pharmacokinetics of t0001 in healthy adult chinese volunteers

Conditions: Rheumatic Diseases

Summary: the purpose of this study to assess the mtd and pharmacokinetics of t0001 in healthy adult chinese volunteers.


Eligibility criteria:
inclusion criteria: * healthy adult volunteers, able to give written informed consent for participation in the trial; * men or women 50% each , aged 18-45 years old; * subjects must have physical examination required and prove medical fitness in 7 days before the clinical starts. bmi should be between 19-24, similar bmi among subjects enrolled at the same time; exclusion criteria: * acute or chronic infection, or history of active tuberculosis; * history of diseases of central nervous system, cardiovascular system, kidney, liver ( specified liver function index), digestive system, respiratory system , metabolism system; * subjects who use 5 unit doses tuberculin skin test are positive( 48-72 hour scleroma reading≥5mm); * subjects with a history of mental problems; * pregnant and lactating women or women who plan to be pregnant in 3 months; * occurence of clinical significant abnormal laboratory examination value during the screening; * subjects that lack of understanding ,communication or collaboration, and can't comply with the protocols; * subjects that the researchers considered to be not appropriate to participate the trial due to other reasons;